Compare TBPH & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | CYRX |
|---|---|---|
| Founded | 2013 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.9M | 814.9M |
| IPO Year | 2013 | 2008 |
| Metric | TBPH | CYRX |
|---|---|---|
| Price | $17.03 | $16.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $18.40 | $13.31 |
| AVG Volume (30 Days) | 345.7K | ★ 436.7K |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 279.13 | 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | $15,386,000.00 | ★ $176,177,000.00 |
| Revenue This Year | $8.46 | $11.06 |
| Revenue Next Year | N/A | $8.45 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.08 | $7.61 |
| 52 Week High | $21.03 | $17.20 |
| Indicator | TBPH | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 56.83 |
| Support Level | $16.80 | $14.55 |
| Resistance Level | $17.11 | $16.87 |
| Average True Range (ATR) | 0.06 | 0.59 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.69 | 69.08 |
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.